Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics

Canakinumab, an anti-interleukin-1β (IL-1β) monoclonal antibody, is approved for cryopyrin-associated periodic syndromes and is under investigation for the management of other inflammatory disorders. In this study, population-based pharmacokinetic–pharmacodynamic models were developed to understand...

Descripción completa

Detalles Bibliográficos
Autores principales: Ait-Oudhia, S, Lowe, P J, Mager, D E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603473/
https://www.ncbi.nlm.nih.gov/pubmed/23835885
http://dx.doi.org/10.1038/psp.2012.6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603473/
https://www.ncbi.nlm.nih.gov/pubmed/23835885
http://dx.doi.org/10.1038/psp.2012.6

Ejemplares similares